Bristol Myers Squibb Highlights Opdivo Regime Data In Lung Cancer Settings
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb & Co (NYSE:BMY) announced positive data from the Phase 3 CheckMate -77T trial of the perioperative regimen of neoadjuvant Opdivo with chemotherapy for non-small cell lung cancer. The Opdivo regime reduced the risk of disease recurrence, progression or death by 42% compared to neoadjuvant chemotherapy and placebo. The company's shares are down 0.17% at $57.28.
October 18, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Opdivo regime shows promising results in Phase 3 trial, potentially boosting the company's oncology portfolio. However, the company's shares are slightly down.
The positive results from the Phase 3 trial of Opdivo regime could potentially boost Bristol Myers Squibb's oncology portfolio and its market position. However, the slight decrease in the company's shares indicates that the market has not yet fully reacted to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100